Standard BioTools(NASDAQ) FLDM

Standard BioTools makes high-tech machines and chemicals that help scientists study diseases. These tools assist researchers in finding and testing new medicines more quickly. They serve hospitals, universities, and drug companies looking for deeper health insights.

What’s in the Lab?

• CyTOF Technology: Mass spectrometry platforms used to identify proteins in blood and tissue; identifies molecules by their weight to help researchers understand immune responses.
• Hyperion Systems: Spatial biology tools that analyze how cells are organized within a tissue sample while preserving their physical location.
• Biomark X9: High-speed genomics systems used for quantitative polymerase chain reaction, which is a technique that measures gene activity by copying genetic material.
• Consumables: Proprietary chemicals and testing kits required to run the instruments; accounted for 52% of total revenue in the first quarter of 2026.

Selling the Old to Fund the New

• Completed the sale of the SomaScan Business to Illumina in January 2026 for approximately $388 million in total initial consideration.
• Consolidated research and development functions into its facility in Singapore and moved its corporate headquarters to Boston in late 2025.
• Changed its name from Fluidigm Corporation in April 2022 to signal a strategic shift toward standardized tools for the life sciences industry.
• Established a royalty agreement with Illumina for future income based on the sales of specific protein-sequencing library preparation kits.

Specialized Global Reach

Standard BioTools focuses on multi-omics, which is the simultaneous study of different biological molecules like proteins and genes. The company maintains a global distribution network serving customers across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.

Performance by the Numbers

• Net income reached $127 million in the first quarter of 2026, up 588% from the previous year following the gain from a business sale.
• Total revenue hit $21 million in the first quarter of 2026, representing a 5% increase from $20 million in the same period of 2025.
• Operating losses narrowed to $12.5 million in the first quarter of 2026, improving by 54% compared to the prior year.
• Consumables revenue grew 35% to $11 million in the first quarter of 2026, driven by higher customer usage of laboratory platforms.

The Path Forward

Standard BioTools has transitioned from a broad biotech firm into a leaner provider of specialized research instruments and high-margin consumables. By divesting legacy businesses and cutting operational costs, the company has bolstered its cash reserves to support its long-term focus on multi-omics technology.